If you're in your mid-to-late 40s and feeling anxious in a way you didn't before, there is a well-established neurobiological reason for it. While life circumstances and psychological history can shape how anxiety is experienced, the primary driver in perimenopause is neurochemical: hormonal volatility directly disrupts the systems that regulate calm. Anxiety driven by that dysregulation responds to different interventions than anxiety from stress or a generalised anxiety disorder.

How Common Is New-Onset Anxiety in Perimenopause?

The Study of Women's Health Across the Nation (SWAN), which tracked more than 3,000 women across the menopausal transition, found that women were 2–4 times more likely to develop significant anxiety symptoms during perimenopause than during their premenopausal years, even when controlling for prior mental health history and life stress.[1]

The study identified new-onset anxiety, not a worsening of pre-existing conditions (though those also worsen in many women). Women who described themselves as emotionally stable throughout their adult lives were among those affected.

The Neurobiological Explanation

Estrogen and GABA

GABA (gamma-aminobutyric acid) is the brain's primary inhibitory neurotransmitter. When GABA activity is high, the nervous system is calm. When it is low, the nervous system is overactive and anxious. This is the system that benzodiazepine medications (diazepam, lorazepam) work on: they enhance GABA activity, which is why they reduce anxiety quickly.

Your body produces its own GABA-enhancing molecules called neurosteroids, particularly allopregnanolone, which is derived from progesterone. Estrogen plays a central role in regulating the sensitivity of GABA-A receptors to these neurosteroids.[2]

When estrogen fluctuates rapidly (as it does throughout early perimenopause), GABA-A receptor sensitivity fluctuates with it. Your brain's anxiety-regulating system becomes less reliable, not because you're under more stress, but because the underlying hardware is less stable.[2][3]

Estrogen and Serotonin

Estrogen supports serotonin synthesis, receptor binding, and the efficiency of serotonin transport.[4] This is why SSRIs (which increase serotonin availability) are prescribed not just for mood but also for hot flashes, because the vasomotor system and the mood regulation system share underlying neurochemistry.

When estrogen declines and fluctuates, serotonin signalling becomes less consistent. The result can include irritability, emotional reactivity, low mood, and a lowered resilience to stress that feels like anxiety.

The HPA Axis

The hypothalamic-pituitary-adrenal (HPA) axis is the brain-hormone cascade that governs your stress response. Cortisol is its main output. Estrogen plays a regulatory role in cortisol feedback: it helps your system return to baseline after a stressor by supporting glucocorticoid receptor sensitivity.[5]

When estrogen is low or fluctuating, the HPA axis runs hotter. Stress responses are more easily triggered and take longer to resolve. This is experienced as feeling more reactive, more easily overwhelmed, or as though the dial has been turned up on everything.

Why Fluctuation Is Worse Than Decline

The most difficult phase for many women is not when estrogen is consistently low (postmenopause), but during the early-to-mid perimenopausal transition when estrogen is erratic. Estrogen in early perimenopause can spike far above your premenopausal baseline one week and crash below it the next.[6]

This volatility is harder on the nervous system than a stable lower level. Your brain adapts to consistent environments; rapid swings are destabilising. This is why some women find that mood and anxiety actually improve once they're fully postmenopausal.

How Perimenopausal Anxiety Differs from GAD

Generalised anxiety disorder (GAD) is characterised by persistent, diffuse worry across multiple life domains, present for at least six months, often including cognitive symptoms (racing thoughts, difficulty concentrating) and physical symptoms (muscle tension, restlessness, fatigue).[7]

Perimenopausal anxiety can mimic this, but tends to have a different texture:

  • Often more episodic: surges of anxiety that correlate loosely with cycle phase, hot flash events, or night sweats
  • Often more physical: racing heart, chest tightness, a sense of internal vibration or agitation
  • Less accompanied by ruminative worry: many women describe it as anxiety "without content," a physiological state of alarm not attached to a specific worry
  • Frequently worse at night, particularly in the small hours after waking from a vasomotor event

This doesn't mean you cannot also have GAD, or that prior anxiety disorders don't worsen in perimenopause (they often do). But if anxiety is new, appeared alongside other perimenopausal symptoms, and has a more physical and episodic quality, it is more likely to be neurohormonal in origin than a new psychiatric condition.

If anxiety is significantly impairing daily function, if physical symptoms such as chest tightness or palpitations have not been evaluated by a clinician, or if anxiety is accompanied by thoughts of self-harm, seek clinical assessment. A GP or psychiatrist with menopause experience can help clarify whether what you're experiencing is perimenopausal, a separate anxiety disorder, or both.

Why Sleep and Anxiety Reinforce Each Other

Anxiety and sleep disruption in perimenopause are bidirectionally reinforcing. Sleep deprivation directly increases amygdala reactivity and reduces prefrontal control over emotional responses.[8] One bad night of sleep from night sweats increases both the likelihood of anxiety the following day and its intensity.

Over weeks and months of disrupted sleep, a chronic state of elevated anxiety can develop that persists even when sleep improves, because the nervous system has habituated to hypervigilance. Treating sleep disruption is not a secondary concern; it is directly treating anxiety.

What Helps

Hormonal Approaches

For women with significant perimenopausal symptoms who are eligible for hormonal therapy, HRT can address anxiety at the source by stabilising the estrogen fluctuations that drive neurochemical instability.[9] This is not a mood drug in the psychiatric sense; it's restoring the hormonal environment that allowed normal GABA and serotonin function.

The evidence is strongest for women who develop depression and anxiety symptoms during perimenopause with no prior history, and who also have vasomotor symptoms. For this group, some evidence suggests hormonal stabilisation may be more effective than antidepressants.[9][10]

Cognitive Behavioural Therapy

CBT has one of the strongest evidence bases of any non-pharmacological intervention for anxiety disorders, and has been studied specifically in the perimenopausal context.[11] In this population, CBT helps with:

  • Catastrophising about physical symptoms (the racing heart during a hot flash is not a cardiac event)
  • Unhelpful thought patterns about ageing, capability, and identity
  • Behavioural avoidance: withdrawing from situations due to anxiety about hot flashes or unpredictability

CBT does not address the underlying hormonal dysregulation, but it is an effective parallel intervention and may be the most accessible option for many women.

SSRIs and SNRIs

For women who need or prefer non-hormonal treatment, low-dose SSRIs (particularly paroxetine CR, which is FDA-approved for vasomotor symptoms) and SNRIs (particularly venlafaxine and desvenlafaxine) have evidence both for reducing hot flash frequency and for improving mood and anxiety.[12] They work on the downstream neurochemical effects of estrogen fluctuation rather than the fluctuation itself.

Exercise

Regular aerobic exercise reduces HPA axis reactivity, increases BDNF, supports serotonin synthesis, and improves sleep quality.[13] For anxiety specifically, consistent moderate-intensity aerobic activity (including programmes of around 150 minutes per week) has shown meaningful reductions in anxiety and depressive symptoms across multiple trials. Resistance training also shows benefit.

The mechanism is direct: exercise regulates the same systems that estrogen dysregulation disrupts. It is among the most consistently effective tools available without a prescription.

Treating Sleep to Treat Anxiety

Keeping your bedroom cool, using breathable bedding, and having a cool pack accessible all reduce arousal during the night and protect sleep architecture when night sweats are the primary disruptor.

If sleep disruption is multi-factorial (racing thoughts, waking at 3 AM without a hot flash), CBT for insomnia (CBT-I) has strong evidence and is the recommended first-line treatment over sleep medications.[14]

Starting the Right Conversation

New anxiety in perimenopause is a predictable neurobiological consequence of hormonal volatility. The same fluctuations that cause hot flashes and night sweats destabilise GABA receptor sensitivity, serotonin signalling, and HPA axis regulation.

Treating the hormonal transition (through HRT, lifestyle changes, or the non-hormonal options above) addresses the anxiety rather than just managing its symptoms. If anxiety is new for you, appeared alongside other perimenopausal symptoms, or is significantly affecting your quality of life, this context belongs in your conversation with your doctor. A clinician with menopause experience can help determine whether what you're experiencing is perimenopausal, a separate anxiety disorder, or a combination of both, and which interventions are most appropriate for your situation.

References

[1] Bromberger, J. T., Kravitz, H. M., Chang, Y., Randolph, J. F., Jr, Avis, N. E., Gold, E. B., Matthews, K. A. (2013). Does risk for anxiety increase during the menopausal transition? Study of Women's Health Across the Nation. Menopause, 20(5), 488-495. https://doi.org/10.1097/gme.0b013e3182730599

[2] Lovick, T. A. (2013). Estrogen, GABA and anxiety. Pharmacology Biochemistry and Behavior, 107, 37-42. https://doi.org/10.1016/j.pbb.2013.04.007

[3] Belelli, D., Lambert, J. J. (2005). Neurosteroids: endogenous regulators of the GABA-A receptor. Nature Reviews Neuroscience, 6(7), 565-575. https://doi.org/10.1038/nrn1703

[4] Bethea, C. L., Mirkes, S. J., Shively, C. A., Adams, M. R. (2000). Steroid regulation of tryptophan hydroxylase protein in the dorsal raphe of macaques. Biological Psychiatry, 47(6), 562-576. https://doi.org/10.1016/s0006-3223(99)00156-0

[5] Kudielka, B. M., Kirschbaum, C. (2005). Sex differences in HPA axis responses to stress: a review. Biological Psychology, 69(1), 113-132. https://doi.org/10.1016/j.biopsycho.2004.11.009

[6] Schmidt, P. J., Ben Dor, R., Martinez, P. E., et al. (2015). Effects of estradiol withdrawal on mood in women with past perimenopausal depression. JAMA Psychiatry, 72(7), 714-726. https://doi.org/10.1001/jamapsychiatry.2015.0111

[7] American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders (5th ed.). APA Publishing.

[8] Kahn, M., Sheppes, G., Sadeh, A. (2013). Sleep and emotions: Bidirectional links and underlying mechanisms. International Journal of Psychophysiology, 89(2), 218-228. https://doi.org/10.1016/j.ijpsycho.2013.05.010

[9] Freeman, E. W., Sammel, M. D., Liu, L., Gracia, C. R., Nelson, D. B., Hollander, L. (2006). Associations of hormones and menopausal status with depressed mood in women with no history of depression. Archives of General Psychiatry, 63(4), 375-382. https://doi.org/10.1001/archpsyc.63.4.375

[10] Schmidt, P. J., Rubinow, D. R. (2009). Sex hormones and mood in the perimenopause. Annals of the New York Academy of Sciences, 1179, 70-85. https://doi.org/10.1111/j.1749-6632.2009.04978.x

[11] Ayers, B., Smith, M., Hellier, J., Mann, E., Hunter, M. S. (2012). Effectiveness of group and self-help cognitive behavior therapy in reducing problematic menopausal hot flushes and night sweats: A randomised controlled trial. Menopause, 19(7), 749-759. https://doi.org/10.1097/gme.0b013e31823fe835

[12] Loprinzi, C. L., Sloan, J., Stearns, V., et al. (2009). Newer antidepressants and gabapentin for hot flashes: An individual patient pooled analysis. Journal of Clinical Oncology, 27(17), 2831-2837. https://doi.org/10.1200/JCO.2008.19.6253

[13] Stathopoulou, G., Powers, M. B., Berry, A. C., Smits, J. A. J., Otto, M. W. (2006). Exercise interventions for mental health: A quantitative and qualitative review. Clinical Psychology: Science and Practice, 13(2), 179-193. https://doi.org/10.1111/j.1468-2850.2006.00021.x

[14] Qaseem, A., Kansagara, D., Forciea, M. A., et al. (2016). Management of chronic insomnia disorder in adults: A clinical practice guideline from the American College of Physicians. Annals of Internal Medicine, 165(2), 125-133. https://doi.org/10.7326/M15-2175